Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures

This study has been terminated.
(No suitable case available and many techinical error)
Sponsor:
Information provided by (Responsible Party):
Rapat Pittayanon, MD, King Chulalongkorn Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01501474
First received: December 27, 2011
Last updated: July 1, 2014
Last verified: July 2014

December 27, 2011
July 1, 2014
January 2012
July 2014   (final data collection date for primary outcome measure)
Increasing the detection rate of malignant biliary stricture diagnosis by using CholangioFlex (Cofocal) and/or FISH test [ Time Frame: up to 1 year ] [ Designated as safety issue: Yes ]
If investigator can detect malignant biliary stricture more than present, the care giver can treat these patients properly. Consequently, the mortality rate of malignant biliary stricture will be decrease.
Same as current
Complete list of historical versions of study NCT01501474 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures

Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures

Objectives

  1. To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
  2. To assess the sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis

Study design One academic center, prospective, diagnostic study

Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital

Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures

Objectives

  1. To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
  2. To assess the sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis

Study design One academic center, prospective, diagnostic study

Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital

Inclusion Criteria

  1. Age > 20 year-old
  2. All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
  3. All patients have to sign the consent form Exclusion Criteria

1.Cannot follow up for 1 year 2.Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants 3.Pregnancy 4.History of fluorescein allergy

Timeline: From January 2012 to December 2013

Sample size Due to no study in Thai population before, investigator will perform pilot study in 50 malignant biliary stricture patients

Method

  1. All patients had informed the consent.
  2. Take the history, physical examination and then fill in the record form 3.5 ml of blood sampling for CA19-9 and 20 ml for further test by keeping in -20c temperature for 5 years

4.Set confocal endomicroscopy at the same session of ERCP 5.After successfully cannulation;

  • 10% Fluorescein sodium 2.5 ml was injected intravenously.
  • Confocal endomicroscopy (CholangioFlex) was performed at the suspected area. The video will record the images with Cellvizio program recorder.

    6.Brush cytology was performed 7.Record the duration and complication of the procedure 8.Send the tissues to one clinically-blinded GI pathologist for pathological diagnosis and FISH test 9.Compare the pathology and FISH report and endoscopic finding 10.Report the result According to Miami-criteria 2009, the Criteria for malignant biliary stricture from CholangioFlex are one of the followings;

    1. Thick branching bands (>20 microns)
    2. Dark clumps or glands (usually measuring > 60 microns)
    3. Bright and tortuous vessels

      Follow up

  • The patients who are diagnosed malignant biliary obstruction will be treated as standard management
  • The patients who are not diagnosed malignant biliary obstruction will be followed up every 3 months for 1 year
  • The gold standard is pathology or clinical of malignancy including evidence of metastasis.

Statistical analysis Sensitivity, specificity, negative predictive value(NPV), positive predictive value(PPV) and accuracy by McNemar's test

Ethical considerations There is not a clearly evidence about the significant serious side effect of fluorescein injection. If the patients have side effects during the research, the procedure will be terminated and the patients will be in the responsibility of all investigators.

Expected benefit and application

  1. Increase rate of malignant biliary stricture diagnosis by using CholangioFlex and/or FISH test
  2. Decrease the mortality rate of malignant biliary stricture
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Brush cytology and FISH test

Non-Probability Sample

Due to no study in Thai population before, investigator will perform pilot study in 50 malignant biliary stricture patients

Malignant Biliary Strictures
Not Provided
CholangioFlex and Fluorescent in situ Hybridization(FISH)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
5
July 2014
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age > 20 year-old
  2. All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
  3. All patients have to sign the consent form

Exclusion Criteria:

  1. Cannot follow up for 1 year
  2. Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants
  3. Pregnancy
  4. History of fluorescein allergy
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Thailand
 
NCT01501474
RP004
No
Rapat Pittayanon, MD, King Chulalongkorn Memorial Hospital
King Chulalongkorn Memorial Hospital
Not Provided
Principal Investigator: Rapat Pittayanon, MD Chulalongkorn Hospital
Study Director: Rungsun Rerknimitr, Professor Chulalongkorn Hospital
King Chulalongkorn Memorial Hospital
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP